The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Abstract
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed. Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of 19 PD patients who had not previously been exposed to Levodopa. Patients provided two stool samples prior to and two samples 90 days after starting Levodopa. Motor impairment (MDS-UPDRS Part III), diet, and other patient characteristics were assessed. 16S rRNA gene amplicon sequencing was used to characterize the microbiota. We examined, cross-sectionally and longitudinally, the associations between Levodopa use and alpha and beta diversity and performed feature-wise, multivariate modeling to identify taxa associated longitudinally with Levodopa use and with improvement in motor function after Levodopa administration. Results: We did not observe significant differences in alpha or beta diversity before vs. after initiation of Levodopa. In longitudinal feature-wise analyses, at the genus level, no taxa were significantly associated with Levodopa use after false discovery rate (FDR) correction (q < 0.05). We observed a marginally lower relative abundance of bacteria belonging to Clostridium group IV in PD patients who experienced a medium or large improvement in motor impairment in response to Levodopa compared to those with a small response [β = −0.64 (SE: 0.18), p-trend: 0.00015 p-FDR: 0.019]. Conclusions: In this study, Levodopa was not associated with changes in microbiota composition in this longitudinal analysis. The association between abundance of Clostridium group IV and short-term motor symptom response to Levodopa is preliminary and should be investigated in larger, longer-term studies, that include a control group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Population-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Extensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Chemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521
Research works printed but not linked: 26
- Kalia, 2015, Parkinson's disease, Lancet., 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
- Schwiertz, 2018, Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease, Parkinsonism Related Disord., 50, 104, 10.1016/j.parkreldis.2018.02.022 · DOI · Paper page
- Dehay, 2016, Alpha-synuclein propagation: New insights from animal models, Mov Disord., 31, 161, 10.1002/mds.26370 · DOI
- Petrov, 2017, Analysis of gut microbiota in patients with Parkinson's disease, Bull Exper Biol Med., 162, 734, 10.1007/s10517-017-3700-7 · DOI · Paper page
- Unger, 2016, Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls, Parkinsonism Related Disord., 32, 66, 10.1016/j.parkreldis.2016.08.019 · DOI · Paper page
- Bedarf, 2017, Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients, Genome Med., 9, 39, 10.1186/s13073-017-0428-y · DOI · Paper page
- Hopfner, 2017, Gut microbiota in Parkinson disease in a northern German cohort, Brain Res., 1667, 41, 10.1016/j.brainres.2017.04.019 · DOI · Paper page
- Heintz-Buschart, 2017, The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder, Mov Disord., 33, 88, 10.1002/mds.27105 · DOI · Paper page
- Pereira, 2017, Oral and nasal microbiota in Parkinson's disease, Parkinsonism Related Disord., 38, 61, 10.1016/j.parkreldis.2017.02.026 · DOI · Paper page
- Sampson, 2016, Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease, Cell., 167, 1469, 10.1016/j.cell.2016.11.018 · DOI · Paper page
- Qian, 2018, Alteration of the fecal microbiota in Chinese patients with Parkinson's disease, Brain Behav Immun., 70, 194, 10.1016/j.bbi.2018.02.016 · DOI · Paper page
- Zimmermann, 2019, Mapping human microbiome drug metabolism by gut bacteria and their genes, Nature., 570, 462, 10.1038/s41586-019-1291-3 · DOI · Paper page
- Barichella, 2019, Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism, Mov Disord., 34, 396, 10.1002/mds.27581 · DOI · Paper page
- Hughes, 1993, A clinicopathologic study of 100 cases of Parkinson's disease, Arch Neurol., 50, 140, 10.1001/archneur.1993.00540020018011 · DOI · Paper page
- Goetz, 2004, Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations, Mov Disord., 19, 1020, 10.1002/mds.20213 · DOI · Paper page
- Kozich, 2013, Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform, Appl Environ Microbiol., 79, 5112, 10.1128/AEM.01043-13 · DOI · Paper page
- Edgar, 2013, UPARSE: highly accurate OTU sequences from microbial amplicon reads, Nature methods., 10, 996, 10.1038/nmeth.2604 · DOI · Paper page
- Bolyen, 2019, Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat Biotechnol., 37, 852, 10.1038/s41587-019-0209-9 · DOI · Paper page
- Mortensen, 1996, Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease, Scand J Gastroenterol Suppl., 216, 132, 10.3109/00365529609094568 · DOI · Paper page
- Heinken, 2019, Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease, Microbiome., 7, 75, 10.1186/s40168-019-0689-3 · DOI · Paper page
- Asano, 2012, Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice, Am J Physiol Gastrointest Liver Physiol., 303, G1288, 10.1152/ajpgi.00341.2012 · DOI · Paper page
- Umesaki, 1999, Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system, Infect Immunity., 67, 3504, 10.1128/IAI.67.7.3504-3511.1999 · DOI · Paper page
- Atarashi, 2011, Induction of colonic regulatory T cells by indigenous Clostridium species, Science., 331, 337, 10.1126/science.1198469 · DOI · Paper page
- Tansey, 2007, Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention, Exp Neurol., 208, 1, 10.1016/j.expneurol.2007.07.004 · DOI · Paper page
- Saunders, 2012, CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J Neuroimmune Pharmacol., 7, 927, 10.1007/s11481-012-9402-z · DOI · Paper page
- McGeer, 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology., 38, 1285, 10.1212/WNL.38.8.1285 · DOI · Paper page
Cited by
Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial
Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2305 · Cited by 128
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Metadata
- Authors
- Palacios, N., Hannoun, A., Flahive, J., Ward, D., Goostrey, K., Deb, A., & Smith, K. M.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-04
- Volume
- 12
- ISSN
- 1664-2295
- Cited by
- 30
- References
- 14
- Funders
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease. https://app.cochat.ai/papers/10.3389/fneur.2021.574529
- The paper
- Palacios, N., Hannoun, A., Flahive, J., Ward, D., Goostrey, K., Deb, A., & Smith, K. M. (2021). Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2021.574529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.